XML 107 R30.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Revenue from Contracts with Customers (Tables)
12 Months Ended
Dec. 31, 2019
Product sales, net  
Schedule of Disaggregation of Revenues

 

During the years ended December 31, 2019, 2018 and 2017, the Company recorded product sales, net, as follows:

 

 

 

Year Ended December 31,

 

(In thousands)

 

2019

 

 

2018

 

 

2017

 

VIVITROL

 

$

335,365

 

 

$

302,609

 

 

$

269,321

 

ARISTADA/ARISTADA INITIO

 

 

189,134

 

 

 

147,725

 

 

 

93,513

 

Total product sales, net

 

$

524,499

 

 

$

450,334

 

 

$

362,834

 

Manufacturing and royalty revenues  
Schedule of Disaggregation of Revenues

During the years ended December 31, 2019, 2018 and 2017, the Company recorded manufacturing and royalty revenues from its collaboration arrangements as follows:

 

 

 

Year Ended December 31, 2019

 

(In thousands)

 

Manufacturing Revenue

 

 

Royalty Revenue

 

 

Total

 

INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA

 

$

 

 

$

256,947

 

 

$

256,947

 

RISPERDAL CONSTA

 

 

50,433

 

 

 

15,950

 

 

 

66,383

 

AMPYRA/FAMPYRA

 

 

22,071

 

 

 

15,170

 

 

 

37,241

 

Other

 

 

31,750

 

 

 

55,561

 

 

 

87,311

 

 

 

$

104,254

 

 

$

343,628

 

 

$

447,882

 

 

 

 

Year Ended December 31, 2018

 

(In thousands)

 

Manufacturing Revenue

 

 

Royalty Revenue

 

 

Total

 

INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA

 

$

 

 

$

241,423

 

 

$

241,423

 

RISPERDAL CONSTA

 

 

52,770

 

 

 

18,352

 

 

 

71,122

 

AMPYRA/FAMPYRA

 

 

53,044

 

 

 

54,009

 

 

 

107,053

 

Other

 

 

27,214

 

 

 

79,863

 

 

 

107,077

 

 

 

$

133,028

 

 

$

393,647

 

 

$

526,675

 

 

 

 

Year Ended December 31, 2017

 

(In thousands)

 

Manufacturing Revenue

 

 

Royalty Revenue

 

 

Total

 

INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA

 

$

 

 

$

214,931

 

 

$

214,931

 

RISPERDAL CONSTA

 

 

64,793

 

 

 

20,129

 

 

 

84,922

 

AMPYRA/FAMPYRA

 

 

55,373

 

 

 

61,646

 

 

 

117,019

 

Other

 

 

32,655

 

 

 

55,781

 

 

 

88,436

 

 

 

$

152,821

 

 

$

352,487

 

 

$

505,308